How does 0QLR's PE Ratio compare to its peers?

0QLR is good value based on its Price-To-Earnings Ratio (17.5x) compared to the peer average (22.1x).

How does 0QLR's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0QLR is good value based on its Price-To-Earnings Ratio (17.5x) compared to the European Pharmaceuticals industry average (20.6x).

What is 0QLR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QLR is good value based on its Price-To-Earnings Ratio (17.5x) compared to the estimated Fair Price-To-Earnings Ratio (33.8x).

What is the Fair Price of 0QLR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0QLR (CHF91.06) is trading below our estimate of [[fair value]] (CHF243.2)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Novartis (LSE:0QLR) - Stock Price, News & Analysis

0QLR Stock Overview

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details

0QLR fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 62.6% below our estimate of its fair value

Earnings are forecast to grow 6.99% per year

Earnings grew by 62.3% over the past year

Pays a reliable dividend of 3.48%

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Novartis AG Competitors

AstraZeneca

LSE:AZN

UK£155.4b

GSK

LSE:GSK

UK£53.2b

Hikma Pharmaceuticals

LSE:HIK

UK£4.1b

Roche Holding

SWX:ROG

CHF 201.3b

Price History & Performance

Summary of all time highs, changes and price drops for Novartis
Historical stock prices
Current Share Price	CHF 91.06
52 Week High	CHF 115.98
52 Week Low	CHF 83.61
Beta	0.51
11 Month Change	-9.75%
3 Month Change	-9.47%
1 Year Change	7.20%
33 Year Change	18.80%
5 Year Change	-0.48%
Change since IPO	26.44%

Recent updates

Shareholder Returns

	0QLR	GB Pharmaceuticals	GB Market
7D	-1.4%	-2.2%	-0.3%
1Y	7.2%	-3.2%	6.1%

Return vs Industry: 0QLR exceeded the UK Pharmaceuticals industry which returned -3.2% over the past year.

Return vs Market: 0QLR exceeded the UK Market which returned 6.1% over the past year.

Price Volatility

Is 0QLR's price volatile compared to industry and market?
0QLR volatility
0QLR Average Weekly Movement	2.0%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0QLR has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0QLR's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	76,057	Vas Narasimhan	www.novartis.com

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
0QLR fundamental statistics
Market cap	CHF 182.05b
Earnings (TTM)	CHF 10.38b
Revenue (TTM)	CHF 44.07b

17.5x

P/E Ratio

4.1x

P/S Ratio

Is 0QLR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QLR income statement (TTM)
Revenue	US$49.94b
Cost of Revenue	US$12.07b
Gross Profit	US$37.87b
Other Expenses	US$26.11b
Earnings	US$11.76b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 31, 2025

Earnings per share (EPS)	5.88
Gross Margin	75.83%
Net Profit Margin	23.55%
Debt/Equity Ratio	69.8%

How did 0QLR perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

68%

Payout Ratio

0QLR Stock Overview

Rewards

Risk Analysis

Novartis AG Competitors

LSE:AZN

UK£155.4b

LSE:GSK

UK£53.2b

LSE:HIK

UK£4.1b

SWX:ROG

CHF 201.3b

Price History & Performance

Recent News & Updates

New minor risk - Earnings quality

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Third quarter 2024 earnings released: EPS: US$1.59 (vs US$0.73 in 3Q 2023)

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis Receives Positive CHMP Opinion for Kisqali to Help Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Novartis AG, Annual General Meeting, Mar 07, 2025

Recent updates

New minor risk - Earnings quality

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Third quarter 2024 earnings released: EPS: US$1.59 (vs US$0.73 in 3Q 2023)

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis Receives Positive CHMP Opinion for Kisqali to Help Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Second quarter 2024 earnings released: EPS: US$1.60 (vs US$1.09 in 2Q 2023)

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

First quarter 2024 earnings released: EPS: US$1.32 (vs US$1.02 in 1Q 2023)

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Upcoming dividend of CHF3.30 per share

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Final dividend of CHF3.30 announced

New minor risk - Earnings quality

Novartis AG Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$4.13 (vs US$3.19 in FY 2022)

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Third quarter 2023 earnings released: EPS: US$0.73 (vs US$0.73 in 3Q 2022)

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Shareholder Returns

Price Volatility

About the Company

Novartis AG Fundamentals Summary

17.5x

4.1x

Earnings & Revenue

Dividends

3.5%

68%